figshare
Browse
40364_2021_271_MOESM1_ESM.docx (796.08 kB)

Additional file 1 of A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer

Download (796.08 kB)
journal contribution
posted on 2021-04-13, 03:36 authored by Pin Zhang, Binghe Xu, Lin Gui, Wenna Wang, Meng Xiu, Xiao Zhang, Guilan Sun, Xiaoyu Zhu, Jianjun Zou
Additional file 1: Online supplemental figures and tables.docx. Figure S1. Linear plot of concentration-time profile for dalpiciclib by dose. Table S1. Dose modifications after DLT assessment period. Table S2. Treatment emergent AEs occurring in ≥2 patients and AEs of special interest. Table S3. Pharmacokinetics and pharmacological characteristics of CDK4/6 inhibitors.

Funding

Jiangsu Hengrui Medicine Co., Ltd

History

Usage metrics

    Biomarker Research

    Categories

    Keywords

    Cyclin-dependent kinase 4/6 inhibitorAdvanced breast cancerFirst-in-human trial

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC